Specific features of the use of alogliptin in various groups of patients with type 2 diabetes mellitus: additional results of the ENTIRE study

BACKGROUND: Since the obtaining of data on the effect of Alogliptin towards the lipid profile, body weight and blood pressure (BP) of patients, the additional analysis of the results of the ENTIRE study, completed in the Russian Federation in 2018, was conducted.

AIMS: Assess the dynamics of HbA_1c, body weight, fats indices, blood pressure (BP), and characterize the profile of the patient who received the maximum clinical benefit on treatment of Alogliptin therapy in the ENTIRE study.

MATERIALS AND METHODS: A prospective non-interventional observational study that included patients aged 18 years and older with first-onset type 2 diabetes mellitus (T2DM) or patients with T2DM who did not achieve their glycemic targets during the previous therapy.

RESULTS: A decrease in glycated hemoglobin (HbA_1c) by more than 0.5% was detected in 73.5% of patients. The most significant absolute decrease of HbA_1c was noticed in patients with initially higher values. Younger patients with a shorter duration of T2DM showed the more often compensation of carbohydrate metabolism. The average loss of weight was -2.6±4.2 kg. 76.6% of patients showed the loss of weight. The most significant decrease in body weight was noticed in patients with a large initial body mass index and a shorter duration of the disease. 74.7% of patients showed a decrease of the level of low-density lipoproteins (LDL). The most significant absolute decrease in LDL was noticed in patients with initially higher values and more often in younger people with a shorter duration of T2DM. The average decrease in systolic blood pressure (BP) was 5.9±0.3 mm Hg; the average decrease in diastolic blood pressure (BP) was 2.7±0.2 mm Hg. 59% of patients showed decrease of blood pressure during the group analyzing. The most frequent BP reduction was observed in younger patients with shorter duration of T2DM. At the same time, a more significant absolute decrease in blood pressure was noticed in patients with initially higher indicators, and an increase, on the contrary, was observed in patients with initially lower indicators.

CONCLUSIONS: The intensification of Alogliptin therapy allowed to achieve the compensation of carbohydrate metabolism, moderate decrease of body weight, blood pressure and LDL indices within the majority of patients with T2DM. The most frequent achievement of HbA_1c targets was noticed in young patients with a shorter duration of T2DM.

type 2 diabetes mellitus, dipeptidyl peptidase-4 inhibitors, alogliptin

1. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск // Сахарный диабет. — 2019. — Т.22. — №S1-1. — С. 1–144. [Dedov II, Shestakova MV, Mayorov AYu, at al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AYu. 9th edition. Diabetes Mellitus. 2019;22(S1-1):1–121. (In Russ).] doi: 10.14341/DM221S1.

2. Nauck MA, Ellis GC, Fleck PR, et al., Group AS 008. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46−55. doi: 10.1111/j.1742-1241.2008.01933.x.

3. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315−2317. doi: 10.2337/dc08-1035.

4. Шестакова М.В., Качко В.А. ENTIRE: исследование реальной клинической практики применения алоглиптина в терапии пациентов с сахарным диабетом 2 типа в РФ // РМЖ. — 2019. — T.27. — №8-1. — С. 3–10. [Shestakova MV, Kachko VA. ENTIRE: real clinical practice study on alogliptin application in the treatment of patients with type 2 diabetes mellitus in the Russian Federation. RMG. 2019;27(8-1):3–10. (In Russ).]

5. Eliasson B, Möller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55:915–925. doi: 10.1007/s00125-011-2447-3.

6. White WB, Cannon CP, Heller SR, et al. Alogliptin after Acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327−1335. doi: 10.1056/NEJMoa1305889.

7. Home PD, Shen C, Hasan MI, et al. Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care. 2014;37(5):1237−1245. doi: 10.2337/dc13-2413.

8. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239−1246. doi: 10.1111/dom.12377.

9. Шестакова М.В. Опыт применения ситаглиптина (первого ингибитора ДПП-4) в лечении сахарного диабета 2 типа в Российской Федерации: результаты наблюдательной программы «Диа-Да» // Сахарный диабет. — 2010. — №3. — С. 57–60. [Shestakova MV. Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation: results of the Dia-Da observation program. Diabetes Mellitus. 2010;(3):57–60. (In Russ).]

10. Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519−1529. doi: 10.1016/S0140-6736(19)32131-2.

11. Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther. 2012;29(9):736−746. doi: 10.1007/s12325-012-0045-5.

12. Mita T, Katakami N, Yoshii H, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139−148. doi: 10.2337/dc15-0781.

13. Xiao C, Dash S, Morgantini C, et al. Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes. 2014;63(7):2394−2401. doi: 10.2337/db13-1654.

14. Nauck MA, Meier JJ, Cavender MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849−870. doi: 10.1161/CIRCULATIONAHA.117.028136.

15. Ogawa S, Ishiki M, Nako K, et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223(2):133−135. doi: 10.1620/tjem.223.133.

16. Duvnjak L, Blaslov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2016;8:26. doi: 10.1186/s13098-016-0144-6.

17. Evans M, Schweizer A, Foley JE. Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: a pooled analysis in> 2,000 previously drug-naïve patients with type 2 diabetes mellitus. Vasc Health Risk Manag. 2016;12:337−340. doi: 10.2147/VHRM.S112148.

18. Chen K, Zhuo T, Wang J, Mei Q. Saxagliptin upregulates nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus. Metab Syndr Relat Disord. 2018;16(7):336−341. doi: 10.1089/met.2018.0010.

19. Yuasa S, Sato K, Furuki T, et al. Primary care-based investigation of the effect of sitagliptin on blood pressure in hypertensive patients with type 2 diabetes. J Clin Med Res. 2017;9(3):188−192. doi: 10.14740/jocmr2820w.

20. Mason RP, Jacob RF, Kubant R, et al. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012;60(5):467−473. doi: 10.1097/FJC.0b013e31826be204.

21. Zhang J, Chen Q, Zhong J, et al. DPP-4 Inhibitors as potential candidates for anti-hypersensitive therapy: improving vascular inflammation and assisting the action of traditional antihypertensive drugs. Front Immunol. 2019;10:1050. doi: 10.3389/fimmu.2019.01050.